Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.
作者信息
von Lueder Thomas G, Sangaralingham S Jeson, Wang Bing H, Kompa Andrew R, Atar Dan, Burnett John C, Krum Henry
机构信息
Department of Epidemiology and Preventive Medicine, Monash Center of Cardiovascular Research and Education in Therapeutics, Monash University, Alfred Hospital, Melbourne, VIC 3004, Australia.
出版信息
Circ Heart Fail. 2013 May;6(3):594-605. doi: 10.1161/CIRCHEARTFAILURE.112.000289.
Abstract
摘要
相似文献
1
Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.肾素-血管紧张素阻断联合利钠肽系统增强：对抗心力衰竭的新型治疗理念。
Circ Heart Fail. 2013 May;6(3):594-605. doi: 10.1161/CIRCHEARTFAILURE.112.000289.
2
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.血管紧张素受体拮抗剂与中性内肽酶抑制剂联合使用
Circulation. 2016 Mar 15;133(11):1115-24. doi: 10.1161/CIRCULATIONAHA.115.018622.
3
Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.慢性心力衰竭作为利钠肽系统有效性降低的一种状态：对治疗的启示。
Eur J Heart Fail. 2017 Feb;19(2):167-176. doi: 10.1002/ejhf.656. Epub 2016 Oct 21.
4
Angiotensin Receptor-Neprilysin Inhibition.血管紧张素受体-中性内肽酶抑制作用
J Cardiovasc Pharmacol Ther. 2017 Jul;22(4):356-364. doi: 10.1177/1074248416683049. Epub 2016 Dec 28.
5
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.联合抑制 Neprilysin 和肾素-血管紧张素系统治疗心力衰竭。
JACC Heart Fail. 2014 Dec;2(6):663-70. doi: 10.1016/j.jchf.2014.09.001. Epub 2014 Oct 8.
6
Sacubitril/Valsartan (LCZ696) in Heart Failure.沙库巴曲缬沙坦（LCZ696）用于心力衰竭治疗
Handb Exp Pharmacol. 2017;243:133-165. doi: 10.1007/164_2016_77.
7
Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.中性肽链内切酶抑制剂LCZ-696（沙库巴曲/缬沙坦）的药代动力学、药效学及降压作用
J Am Soc Hypertens. 2017 Jul;11(7):461-468. doi: 10.1016/j.jash.2017.04.012. Epub 2017 May 25.
8
Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.血管紧张素受体脑啡肽酶抑制剂（ARNi）：一类新型药物的临床研究
Int J Cardiol. 2017 Jan 1;226:136-140. doi: 10.1016/j.ijcard.2016.06.083. Epub 2016 Jun 23.
9
The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.心力衰竭中的中性肽链内切酶途径：沙库巴曲缬沙坦应用的综述与指南
Heart. 2016 Sep 1;102(17):1342-7. doi: 10.1136/heartjnl-2014-306775. Epub 2016 May 20.
10
Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.沙库巴曲缬沙坦双重抑制血管紧张素受体和中性肽链内切酶在慢性收缩性心力衰竭中的应用：解读新的PARADIGM研究
Ann Pharmacother. 2015 Nov;49(11):1237-51. doi: 10.1177/1060028015593093. Epub 2015 Jul 14.
引用本文的文献
1
Multi-Target In-Silico modeling strategies to discover novel angiotensin converting enzyme and neprilysin dual inhibitors.多靶点计算机模拟策略发现新型血管紧张素转换酶和 Neprilysin 双重抑制剂。
Sci Rep. 2024 Jul 10;14(1):15991. doi: 10.1038/s41598-024-66230-7.
2
Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF.精准心脏病学：射血分数保留的心力衰竭（HFpEF）和射血分数中间值的心力衰竭（HFmrEF）的靶向表型治疗
Int J Heart Fail. 2024 Mar 25;6(2):47-55. doi: 10.36628/ijhf.2023.0058. eCollection 2024 Apr.
3
Relationship between heart failure and intestinal inflammation in infants with congenital heart disease.先天性心脏病婴儿心力衰竭与肠道炎症的关系。
BMC Microbiol. 2024 Mar 25;24(1):98. doi: 10.1186/s12866-024-03229-0.
4
What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence.高血压性射血分数保留型心力衰竭的当前最佳药物治疗方法是什么？全证据回顾。
Am J Hypertens. 2024 Jan 1;37(1):1-14. doi: 10.1093/ajh/hpad073.
5
Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.沙库巴曲缬沙坦减轻二尖瓣反流大鼠模型的心脏重构、收缩功能障碍和维持线粒体质量。
Sci Rep. 2023 Jul 16;13(1):11472. doi: 10.1038/s41598-023-38694-6.
6
Sacubitril Valsartan Enhances Cardiac Function and Alleviates Myocardial Infarction in Rats through a SUV39H1/SPP1 Axis.沙库巴曲缬沙坦通过 SUV39H1/SPP1 轴增强大鼠心脏功能并减轻心肌梗死。
Oxid Med Cell Longev. 2022 Sep 22;2022:5009289. doi: 10.1155/2022/5009289. eCollection 2022.
7
Data Mining Identifies and as Biomarker Candidates for Cardiac Hypertrophy.数据挖掘识别出 和 作为心脏肥大的生物标志物候选物。
Life (Basel). 2022 May 12;12(5):726. doi: 10.3390/life12050726.
8
The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure.沙库巴曲缬沙坦与缬沙坦对高血压合并慢性心力衰竭患者血管内皮功能、脂联素、MMP-9 和 BNP 水平的影响比较。
J Healthc Eng. 2022 Feb 18;2022:9494981. doi: 10.1155/2022/9494981. eCollection 2022.
9
Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure.血管紧张素受体脑啡肽酶抑制剂对心力衰竭患者左心房重构及预后的影响。
ESC Heart Fail. 2022 Feb;9(1):667-675. doi: 10.1002/ehf2.13691. Epub 2021 Nov 14.
10
Sacubitril/Valsartan Alleviates Experimental Autoimmune Myocarditis by Inhibiting Th17 Cell Differentiation Independently of the NLRP3 Inflammasome Pathway.沙库巴曲缬沙坦通过独立于NLRP3炎性小体途径抑制Th17细胞分化来减轻实验性自身免疫性心肌炎。
Front Pharmacol. 2021 Sep 15;12:727838. doi: 10.3389/fphar.2021.727838. eCollection 2021.
本文引用的文献
1
Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.阿利吉仑对心力衰竭住院患者出院后死亡率和心力衰竭再入院的影响：ASTRONAUT 随机试验。
JAMA. 2013 Mar 20;309(11):1125-35. doi: 10.1001/jama.2013.1954.
2
RAAS inhibitors and cardiovascular protection in large scale trials.RAAS 抑制剂与大规模临床试验中的心血管保护。
Cardiovasc Drugs Ther. 2013 Apr;27(2):171-9. doi: 10.1007/s10557-012-6424-y.
3
Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.与使用靶向肾素-血管紧张素-醛固酮系统的药物相关的血管性水肿的比较风险。
Arch Intern Med. 2012 Nov 12;172(20):1582-9. doi: 10.1001/2013.jamainternmed.34.
4
Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide.用于收缩性心力衰竭的新型蛋白类治疗药物：慢性皮下注射 B 型利钠肽。
J Am Coll Cardiol. 2012 Dec 4;60(22):2305-12. doi: 10.1016/j.jacc.2012.07.056. Epub 2012 Nov 1.
5
Physiological relevance of hydrolysis of atrial natriuretic peptide by endothelin-converting enzyme-1.内皮素转换酶-1对心钠素的水解作用的生理相关性。
Kobe J Med Sci. 2012 Jun 21;58(1):E12-8.
6
Trends in blood pressure and hypertension detection, treatment, and control 1980 to 2009: the Minnesota Heart Survey.1980 年至 2009 年血压和高血压检测、治疗及控制的趋势：明尼苏达心脏调查。
Circulation. 2012 Oct 9;126(15):1852-7. doi: 10.1161/CIRCULATIONAHA.112.098517. Epub 2012 Sep 7.
7
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.血管紧张素受体脑啡肽酶抑制剂 LCZ696 治疗射血分数保留的心力衰竭的 II 期双盲随机对照试验。
Lancet. 2012 Oct 20;380(9851):1387-95. doi: 10.1016/S0140-6736(12)61227-6. Epub 2012 Aug 26.
8
Heart failure--does it matter whether LVEF is reduced?心力衰竭——左心室射血分数降低是否重要？
Lancet. 2012 Oct 20;380(9851):1363-5. doi: 10.1016/S0140-6736(12)61349-X. Epub 2012 Aug 26.
9
TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure.TRV120027 是血管紧张素 II 型 1 型受体的新型β-arrestin 偏向配体，与呋塞米合用可减轻心力衰竭时的心脏负担并维持肾功能。
Circ Heart Fail. 2012 Sep 1;5(5):627-34. doi: 10.1161/CIRCHEARTFAILURE.112.969220. Epub 2012 Aug 13.
10
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.《2012年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南》：欧洲心脏病学会2012年急性和慢性心力衰竭诊断与治疗特别工作组编著。与欧洲心脏病学会心力衰竭协会（HFA）合作制定。
Eur Heart J. 2012 Jul;33(14):1787-847. doi: 10.1093/eurheartj/ehs104. Epub 2012 May 19.
Zotero 插件